home / stock / adilw / adilw news

ADILW News and Press, Adial Pharmaceuticals Inc Warrant From 03/02/23

Stock Information
Company Name: Adial Pharmaceuticals Inc Warrant
Stock Symbol: ADILW
Market: NASDAQ
Website: adialpharma.com
Menu
ADILW ADILW Quote ADILW Short ADILW News ADILW Articles ADILW Message Board
Get ADILW Alerts

News, Short Squeeze, Breakout and More Instantly...
ADILW - Adial Pharmaceuticals Schedules Business Update Conference Call

CHARLOTTESVILLE, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and relat...
ADILW - Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering

CHARLOTTESVILLE, Va., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and relate...

ADILW - Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering

CHARLOTTESVILLE, Va., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and relate...

ADILW - Adial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder

Type C meeting with FDA set for Second Quarter Plans in Place to Meet with Multiple Regulatory Agencies Throughout Europe CHARLOTTESVILLE, Va., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company...
ADILW - Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed

Adial to focus on late-stage clinical development for AD04 for alcohol use disorder; potential sale of Purnovate to new company formed by former Adial CEO and current Purnovate CEO, William Stilley Potential development/commercial milestone payments of up to $83 million on first three com...

ADILW - Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds Promoted Cary Claiborne to President and Chief Executive Officer CHARLOTTESVILLE, Va., Nov. 14, 2022 (...

ADILW - Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate's PNV-5030 as a Potential Treatment for Chronic Pain

CHARLOTTESVILLE, Va., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., a subsidiary of Adial focused on developing novel molecules targeting the adenosine re...
ADILW - Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate's PNV-6005 as a Potential Treatment for Ulcerative Colitis

CHARLOTTESVILLE, Va., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., a subsidiary of Adial focused on developing novel molecules targeting the adenosine re...

ADILW - Adial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer

Kevin Schuyler appointed Chairman of Adial’s Board William Stilley moves to post of CEO of Adial’s subsidiary, Purnovate Company to host conference call at 8:30 a.m. EDT tomorrow CHARLOTTESVILLE, Va., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Adial Pharmace...

ADILW - Adial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Reported positive topline results for ONWARD™ Phase 3 trial of AD04 for the treatment of Alcohol Use Disorder Pursuing submission of ONWARD™ results with both European and U.S. regulatory agencies Actively exploring potential partnership opportunities for A...
Previous 10 Next 10